242 related articles for article (PubMed ID: 25724527)
101. A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Fairbrother WJ; Wong H; Budha N; Darbonne WC; Peale F; Mamounas M; Royer-Joo S; Yu R; Portera CC; Infante JR
Clin Cancer Res; 2016 Sep; 22(18):4567-73. PubMed ID: 27076626
[TBL] [Abstract][Full Text] [Related]
102. Efficacy and Toxicity of Every 2 Weeks Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate Cancer: A Retrospective Analysis.
Malhotra A; Welch D; Rosenbaum P; Poiesz BJ
Am J Clin Oncol; 2016 Jun; 39(3):266-70. PubMed ID: 24662265
[TBL] [Abstract][Full Text] [Related]
103. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D; Grob JJ; Bechter O; Simonelli M; Doger B; Borbath I; Butler MO; Cheng T; Romano PM; Pons-Tostivint E; Di Nicola M; Curigliano G; Ryu MH; Rodriguez-Vida A; Schadendorf D; Garralda E; Abbadessa G; Demers B; Amrate A; Wang H; Lee JS; Pomponio R; Wang R
Clin Transl Sci; 2024 Feb; 17(2):e13736. PubMed ID: 38362837
[TBL] [Abstract][Full Text] [Related]
104. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
105. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
Rosen LS; Hurwitz HI; Wong MK; Goldman J; Mendelson DS; Figg WD; Spencer S; Adams BJ; Alvarez D; Seon BK; Theuer CP; Leigh BR; Gordon MS
Clin Cancer Res; 2012 Sep; 18(17):4820-9. PubMed ID: 22767667
[TBL] [Abstract][Full Text] [Related]
106. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Hilton JF; Ott PA; Hansen AR; Li Z; Mathew M; Messina CH; Dave V; Ji X; Karpinich NO; Hirschfeld S; Ballas M; Zandberg DP
Cancer Immunol Immunother; 2024 Feb; 73(3):44. PubMed ID: 38349570
[TBL] [Abstract][Full Text] [Related]
107. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
[TBL] [Abstract][Full Text] [Related]
108. The Notch ligand DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate.
Ayllón V; Bueno C; Ramos-Mejía V; Navarro-Montero O; Prieto C; Real PJ; Romero T; García-León MJ; Toribio ML; Bigas A; Menendez P
Leukemia; 2015 Aug; 29(8):1741-53. PubMed ID: 25778099
[TBL] [Abstract][Full Text] [Related]
109. Notch suppresses angiogenesis and progression of hepatic metastases.
Banerjee D; Hernandez SL; Garcia A; Kangsamaksin T; Sbiroli E; Andrews J; Forrester LA; Wei N; Kadenhe-Chiweshe A; Shawber CJ; Kitajewski JK; Kandel JJ; Yamashiro DJ
Cancer Res; 2015 Apr; 75(8):1592-602. PubMed ID: 25744722
[TBL] [Abstract][Full Text] [Related]
110. An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
Yang YL; Jablons D; You L
Transl Lung Cancer Res; 2014 Aug; 3(4):238-41. PubMed ID: 25806306
[TBL] [Abstract][Full Text] [Related]
111. Serum induces transcription of Hey1 and Hey2 genes by Alk1 but not Notch signaling in endothelial cells.
Wöltje K; Jabs M; Fischer A
PLoS One; 2015; 10(3):e0120547. PubMed ID: 25799559
[TBL] [Abstract][Full Text] [Related]
112. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
[TBL] [Abstract][Full Text] [Related]
113. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
114. Notch is a direct negative regulator of the DNA-damage response.
Vermezovic J; Adamowicz M; Santarpia L; Rustighi A; Forcato M; Lucano C; Massimiliano L; Costanzo V; Bicciato S; Del Sal G; d'Adda di Fagagna F
Nat Struct Mol Biol; 2015 May; 22(5):417-24. PubMed ID: 25895060
[TBL] [Abstract][Full Text] [Related]
115. Notch1 is pan-endothelial at the onset of flow and regulated by flow.
Jahnsen ED; Trindade A; Zaun HC; Lehoux S; Duarte A; Jones EA
PLoS One; 2015; 10(4):e0122622. PubMed ID: 25830332
[TBL] [Abstract][Full Text] [Related]
116. Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1.
Pedrosa AR; Trindade A; Fernandes AC; Carvalho C; Gigante J; Tavares AT; Diéguez-Hurtado R; Yagita H; Adams RH; Duarte A
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1134-46. PubMed ID: 25767274
[TBL] [Abstract][Full Text] [Related]
117. Endothelial Cell Metabolism in Health and Disease.
Rohlenova K; Veys K; Miranda-Santos I; De Bock K; Carmeliet P
Trends Cell Biol; 2018 Mar; 28(3):224-236. PubMed ID: 29153487
[TBL] [Abstract][Full Text] [Related]
118. The late-annotated small ORF LSO1 is a target gene of the iron regulon of Saccharomyces cerevisiae.
An X; Zhang C; Sclafani RA; Seligman P; Huang M
Microbiologyopen; 2015 Dec; 4(6):941-51. PubMed ID: 26450372
[TBL] [Abstract][Full Text] [Related]
119. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
120. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
